(Lys9)GLP-1 lacks insulinotropic activity but acts as a potent novel GLP-1 receptor antagonist in vivo.

F.P.M. O'Harte, Brian Green, V.A. Gault, N. Irwin, Mark Mooney, Patrick Harriott, B. Greer, P.R. Flatt

Research output: Contribution to journal › Meeting abstract › peer-review

Cite this

@article{5cf7a10ed5064ac9a178224f39a1817e,

title = "(Lys9)GLP-1 lacks insulinotropic activity but acts as a potent novel GLP-1 receptor antagonist in vivo.",

author = "F.P.M. O'Harte and Brian Green and V.A. Gault and N. Irwin and Mark Mooney and Patrick Harriott and B. Greer and P.R. Flatt",

year = "2004",

language = "English",

volume = "21",

pages = "P26",

journal = "Diabetic Medicine",

issn = "0742-3071",

publisher = "Wiley-Blackwell",

number = "S2",

}

TY - JOUR

T1 - (Lys9)GLP-1 lacks insulinotropic activity but acts as a potent novel GLP-1 receptor antagonist in vivo.

AU - O'Harte, F.P.M.

AU - Green, Brian

AU - Gault, V.A.

AU - Irwin, N.

AU - Mooney, Mark

AU - Harriott, Patrick

AU - Greer, B.

AU - Flatt, P.R.

PY - 2004

Y1 - 2004

M3 - Meeting abstract

VL - 21

SP - P26

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - S2

ER -